Modality
Multispecific
MOA
CAR-T CD19
Target
MDM2
Pathway
Hedgehog
SMAMM
Development Pipeline
Preclinical
Nov 2019
→ Oct 2025
PreclinicalCurrent
NCT05303581
2,953 pts·MM
2019-11→2025-10·Active
2,953 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-165mo agoInterim· MM
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2025-10-16 · 5mo ago
MM
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05303581 | Preclinical | MM | Active | 2953 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |